Allena Pharmaceuticals (ALNA) Names Mark J. Fitzpatrick to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
April 7, 2021 8:01 AM EDTNEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors.
Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development, said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. His extensive experience working with late-stage, rare disease... More
